Canaccord Genuity Cuts Price Target on Calamp Corp. (CAMP) to $23 Following 3Q Report

Pre-Open Stock Movers 12/22: (TKAI) (GSAT) (EYES) Higher; (OVAS) (RHT) (MLHR) Lower (more...)

Today's Pre-Open Movers

Tokai Pharmaceuticals Inc. (NASDAQ: TKAI) 40.6% HIGHER; The company and Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT), today announced that the two companies, together with the shareholders of Otic... More

After-Hours Stock Movers 12/21: (XOMA) (MU) Higher; (OVAS) (RHT) (MLHR) Lower (more...)

Today's After-Hours Movers

OvaScience (NASDAQ: OVAS) 32.7% LOWER; The Company will continue to make AUGMENTSM available to patients at partner clinics in Canada and Japan and maintain its current commercial footprint. However, the Company will slow its commercial expansion, reassess its ongoing and planned clinical studies of AUGMENT, and undertake a corporate restructuring. These changes will enable the Company to extend its cash position into the first quarter of 2019 and increase its focus on the development of OvaPrimeSM and OvaTureSM. In connection with this shift in strategy, President and... More

Calamp Corp. (CAMP) Misses Q3 EPS by 5c; Guides Q4 In-Line

Calamp Corp. (NASDAQ: CAMP) reported Q3 EPS of $0.21, $0.05 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $83.4 million versus the consensus estimate of $83.93 million.

GUIDANCE:

Calamp Corp. sees Q4 2017 EPS of $0.25-$0.31, versus the consensus... More

Calamp Corp. (CAMP) CFO Rick Vitelle to Retire

CalAmp (NASDAQ: CAMP) today announced that its Executive Vice President, Chief Financial Officer and Corporate Secretary, Rick Vitelle, plans to retire from the company after sixteen years of service. Mr. Vitelle will remain as CFO until his successor is found, to ensure an orderly and seamless transition. The company has initiated a comprehensive search... More